应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
SUPN Supernus Pharmaceuticals
交易中 12-23 15:34:30 EST
35.53
+0.10
+0.28%
最高
35.66
最低
34.81
成交量
15.41万
今开
35.12
昨收
35.43
日振幅
2.41%
总市值
19.62亿
流通市值
16.97亿
总股本
5,522万
成交额
544.97万
换手率
0.32%
流通股本
4,776万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Supernus Pharmaceuticals, Inc.盘中异动 下午盘大幅下挫5.00%报35.88美元
市场透视 · 11-15
Supernus Pharmaceuticals, Inc.盘中异动 下午盘大幅下挫5.00%报35.88美元
Supernus Pharmaceuticals, Inc.2024财年第三财季实现净利润38.50百万美元,同比增加340.93%
市场透视 · 11-11
Supernus Pharmaceuticals, Inc.2024财年第三财季实现净利润38.50百万美元,同比增加340.93%
Supernus Pharmaceuticals, Inc.盘中异动 股价大涨9.02%
市场透视 · 11-05
Supernus Pharmaceuticals, Inc.盘中异动 股价大涨9.02%
异动解读 | Supernus Pharmaceuticals业绩亮眼 盘前大涨9.37%
异动解读 · 11-05
异动解读 | Supernus Pharmaceuticals业绩亮眼 盘前大涨9.37%
异动解读 | Supernus Pharmaceuticals公司财报佳绩 盘后大涨6.63%
异动解读 · 11-05
异动解读 | Supernus Pharmaceuticals公司财报佳绩 盘后大涨6.63%
Supernus 制药公司公布截至 9 月 30 日的季度业绩 - 收益摘要
Reuters · 11-05
Supernus 制药公司公布截至 9 月 30 日的季度业绩 - 收益摘要
美国研究综述-埃克森美孚公司、Supernus 制药公司、威廉姆斯-索诺玛公司
Reuters · 09-11
美国研究综述-埃克森美孚公司、Supernus 制药公司、威廉姆斯-索诺玛公司
Supernus Pharmaceuticals, Inc.2024财年第二财季实现净利润19.92百万美元,同比增加2497.11%
自选股智能写手 · 08-12
Supernus Pharmaceuticals, Inc.2024财年第二财季实现净利润19.92百万美元,同比增加2497.11%
Supernus Pharmaceuticals, Inc.股价上涨13.67% 市值涨2.39亿美元
自选股智能写手 · 08-07
Supernus Pharmaceuticals, Inc.股价上涨13.67% 市值涨2.39亿美元
Supernus Pharmaceuticals, Inc.盘中异动 快速跳水5.39%
自选股智能写手 · 08-05
Supernus Pharmaceuticals, Inc.盘中异动 快速跳水5.39%
Supernus Pharmaceuticals Inc 预计每股收益39美分 - 财报前瞻
Reuters · 08-03
Supernus Pharmaceuticals Inc 预计每股收益39美分 - 财报前瞻
公司概况
公司名称:
Supernus Pharmaceuticals
所属市场:
NASDAQ
上市日期:
--
主营业务:
Supernus Pharmaceuticals, Inc.于2005年3月30日在美国特拉华州注册成立,并于2005年12月22日开始运营。该公司是一家专业制药公司,专注于开发和商业化产品,为治疗中枢神经系统疾病,包括神经和精神治疗紊乱。公司有两个专利产品和几个专有候选产品的临床开发,可满足癫痫症和注意力缺陷多动障碍的市场需求。
发行价格:
--
{"stockData":{"symbol":"SUPN","market":"US","secType":"STK","nameCN":"Supernus Pharmaceuticals","latestPrice":35.53,"timestamp":1734986061948,"preClose":35.43,"halted":0,"volume":154127,"delay":0,"floatShares":47762528,"shares":55219273,"eps":1.069713,"marketStatus":"交易中","marketStatusCode":2,"change":0.1,"latestTime":"12-23 15:34:30 EST","open":35.115,"high":35.66,"low":34.805,"amount":5449738.06125,"amplitude":0.024132,"askPrice":35.62,"askSize":315,"bidPrice":35.53,"bidSize":191,"shortable":3,"etf":0,"ttmEps":1.069713,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1734987600000},"adr":0,"listingDate":1335844800000,"adjPreClose":35.43,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":36.09,"preClose":35.43,"latestTime":"08:49 EST","volume":20,"amount":715.6600000000001,"timestamp":1734961790372},"postHourTrading":{"tag":"盘后","latestPrice":35.4305,"preClose":35.43,"latestTime":"16:15 EST","volume":292112,"amount":10349528.107,"timestamp":1734729357331},"volumeRatio":0.352885,"impliedVol":0.4192,"impliedVolPercentile":0.51},"requestUrl":"/m/hq/s/SUPN/wiki","defaultTab":"wiki","newsList":[{"id":"2483334442","title":"Supernus Pharmaceuticals, Inc.盘中异动 下午盘大幅下挫5.00%报35.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483334442","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483334442?lang=zh_cn&edition=full","pubTime":"2024-11-15 04:17","pubTimestamp":1731615445,"startTime":"0","endTime":"0","summary":"北京时间2024年11月15日04时17分,Supernus Pharmaceuticals, Inc.股票出现波动,股价急速下挫5.00%。截至发稿,该股报35.88美元/股,成交量22.8959万股,换手率0.41%,振幅6.45%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中,整体跌幅为1.35%。Supernus Pharmaceuticals, Inc.公司简介:Supernus Pharmaceuticals Inc 是一家专业制药公司,致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115041725abc20745&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115041725abc20745&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SUPN","BK4007"],"gpt_icon":0},{"id":"2482267310","title":"Supernus Pharmaceuticals, Inc.2024财年第三财季实现净利润38.50百万美元,同比增加340.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482267310","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482267310?lang=zh_cn&edition=full","pubTime":"2024-11-11 00:00","pubTimestamp":1731254419,"startTime":"0","endTime":"0","summary":"11月11日,Supernus Pharmaceuticals, Inc.公布财报,公告显示公司2024财年第三财季净利润为38.50百万美元,同比增加340.93%;其中营业收入为1.76亿美元,同比增加14.29%,每股基本收益为0.70美元。机构评级:截至2024年11月11日,当前有4家机构对Supernus Pharmaceuticals, Inc.目标价做出预测,其中目标均价为39.25美元,其中最低目标价为36.00美元,最高目标价为43.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000029abb361fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000029abb361fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SUPN"],"gpt_icon":0},{"id":"2481500384","title":"Supernus Pharmaceuticals, Inc.盘中异动 股价大涨9.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481500384","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481500384?lang=zh_cn&edition=full","pubTime":"2024-11-05 22:32","pubTimestamp":1730817124,"startTime":"0","endTime":"0","summary":"北京时间2024年11月05日22时32分,Supernus Pharmaceuticals, Inc.股票出现波动,股价急速上涨9.02%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中,整体跌幅为0.34%。其相关个股中,Supernus Pharmaceuticals, Inc.、Evotec Se、阿尔凯默斯涨幅较大,Biofrontera Inc.、Canopy Growth Corporation、Evoke Pharma, Inc.较为活跃,换手率分别为2.02%、0.53%、0.39%,振幅较大的相关个股有Aquestive Therapeutics, Inc.、Painreform Ltd.、Supernus Pharmaceuticals, Inc.,振幅分别为7.77%、6.72%、3.89%。Supernus Pharmaceuticals, Inc.公司简介:Supernus Pharmaceuticals Inc 是一家专业制药公司,致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110522320495bdd1f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110522320495bdd1f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SUPN"],"gpt_icon":0},{"id":"1192290637","title":"异动解读 | Supernus Pharmaceuticals业绩亮眼 盘前大涨9.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192290637","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192290637?lang=zh_cn&edition=full","pubTime":"2024-11-05 22:30","pubTimestamp":1730817036,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals公司在2024年第三季度表现出色,财报数据亮眼,引发了股价在盘前大涨9.37%的行情。财报显示,Supernus Pharmaceuticals第三季度实现营收1.76亿美元,同比增长14.2%,超过了分析师预期。此次财报超预期反映了Supernus Pharmaceuticals产品的强劲市场需求和较高的盈利能力。在目前医药行业竞争激烈的环境下,Supernus Pharmaceuticals显现出了较强的商业运营能力。市场普遍预计,公司未来仍将保持良好的发展势头。目前机构分析师给予该股\"买入\"评级,认为公司具有较高的长期成长潜力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SUPN"],"gpt_icon":0},{"id":"1171699565","title":"异动解读 | Supernus Pharmaceuticals公司财报佳绩 盘后大涨6.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171699565","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171699565?lang=zh_cn&edition=full","pubTime":"2024-11-05 16:02","pubTimestamp":1730793756,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals公司最新公布的2024年第三季度财报数据亮眼,业绩超出市场预期,引发股价在盘后大幅上涨。\n\n财报显示,公司第三季度每股收益为69美分,高于分析师平均预期的44美分。营收同比增长14.2%至1.76亿美元,也超过了分析师预期的1.57亿美元。公司本季度净收入达到3850万美元。\n\n优异的财报数据令投资者对Supernus Pharmaceuticals的长期盈利前景充满信心。目前分析师普遍给予该股\"买入\"评级,认为公司具有较强的盈利能力,看好其在医药行业的发展前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SUPN"],"gpt_icon":0},{"id":"2481540442","title":"Supernus 制药公司公布截至 9 月 30 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2481540442","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481540442?lang=zh_cn&edition=full","pubTime":"2024-11-05 15:54","pubTimestamp":1730793258,"startTime":"0","endTime":"0","summary":" * Supernus Pharmaceuticals Inc 报告了截至9月30日的季度调整后每股收益69美分,高于去年同期的每股收益24美分。华尔街预期为每股收益 35 美分至 55 美分。* Supernus Pharmaceuticals Inc公布的本季度每股收益为69美分。* 该公司报告的季度净收入为 3850 万美元。* Supernus Pharmaceuticals Inc 的股价本季度上涨了 11.3%,今年迄今为止上涨了 19.9%。华尔街对 Supernus Pharmaceuticals Inc 的 12 个月目标价中位数为 39.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Supernus 制药公司公布截至 9 月 30 日的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SUPN","BK4007"],"gpt_icon":0},{"id":"2466479575","title":"美国研究综述-埃克森美孚公司、Supernus 制药公司、威廉姆斯-索诺玛公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2466479575","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466479575?lang=zh_cn&edition=full","pubTime":"2024-09-11 15:59","pubTimestamp":1726041541,"startTime":"0","endTime":"0","summary":" 路透9月11日 - 华尔街证券分析师周三调整了对埃克森美孚、Supernus Pharmaceuticals和Williams-Sonoma 等几家美国上市公司的评级和目标价。要点 * Academy Sports and Outdoors Inc :TD Cowen将目标价从54美元上调至56美元 * 埃克森美孚 :Gerdes Energy Research将目标价从中性上调至买入 * 派克-汉尼汾公司 :TD Cowen 将目标价从 500 美元上调至 520 美元 * Supernus Pharmaceuticals Inc :Piper Sandler将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BXP","LU0306807586.USD","LU1668664300.SGD","DV","BK4592","LU0889566641.SGD","LU1169590202.USD","LU2210149790.SGD","LU","LU2087621335.USD","JBI","BK4585","IE00B775SV38.USD","LU2095319765.USD","CPB","BBIO","CNC","ALLY","ZION","FDS","SUPN","LU1150488218.USD","CMA","LU1582986359.USD","AXON","WOOF","LU0149725797.USD","BK4194","BK4588","ASO","CAC","BK4023","LU0640476718.USD","TGI","VRDN","WMB","BK4144","LU1064131342.USD","LU2210150020.SGD","LU1244550221.USD","LU1150488135.SGD","PH","CNOB","LU0323591593.USD","WSM","BK4550","LU0320765489.SGD","XOM"],"gpt_icon":1},{"id":"2458978336","title":"Supernus Pharmaceuticals, Inc.2024财年第二财季实现净利润19.92百万美元,同比增加2497.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458978336","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458978336?lang=zh_cn&edition=full","pubTime":"2024-08-12 00:18","pubTimestamp":1723393123,"startTime":"0","endTime":"0","summary":"8月12日,Supernus Pharmaceuticals, Inc.公布财报,公告显示公司2024财年第二财季净利润为19.92百万美元,同比增加2497.11%;其中营业收入为1.68亿美元,同比增加23.53%,每股基本收益为0.36美元。机构评级:截至2024年8月12日,当前有4家机构对Supernus Pharmaceuticals, Inc.目标价做出预测,其中目标均价为40.50美元,其中最低目标价为38.00美元,最高目标价为43.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408120018549f222ba4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408120018549f222ba4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SUPN"],"gpt_icon":0},{"id":"2457844800","title":"Supernus Pharmaceuticals, Inc.股价上涨13.67% 市值涨2.39亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457844800","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457844800?lang=zh_cn&edition=full","pubTime":"2024-08-07 21:31","pubTimestamp":1723037505,"startTime":"0","endTime":"0","summary":"北京时间2024年08月07日21时31分,Supernus Pharmaceuticals, Inc.股票出现异动,股价快速拉升13.67%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中,整体跌幅为0.98%。其相关个股中,Petiq, Inc.、Supernus Pharmaceuticals, Inc.、Aquestive Therapeutics, Inc.涨幅较大,Petiq, Inc.、Sunshine Biopharma Inc.、苏轩堂较为活跃,换手率分别为3.93%、1.23%、1.21%,振幅较大的相关个股有脑再生科技、Supernus Pharmaceuticals, Inc.、Aquestive Therapeutics, Inc.,振幅分别为7.97%、6.38%、5.14%。Supernus Pharmaceuticals, Inc.公司简介:Supernus Pharmaceuticals Inc 是一家专业制药公司,致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408072131469f17744d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408072131469f17744d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SUPN","BK4007"],"gpt_icon":0},{"id":"2457774549","title":"Supernus Pharmaceuticals, Inc.盘中异动 快速跳水5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457774549","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457774549?lang=zh_cn&edition=full","pubTime":"2024-08-05 22:39","pubTimestamp":1722868741,"startTime":"0","endTime":"0","summary":"北京时间2024年08月05日22时39分,Supernus Pharmaceuticals, Inc.股票出现异动,股价快速下挫5.39%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中,整体跌幅为4.23%。其相关个股中,Incannex Healthcare Inc.、大自然药业、Scilex Holding Company C/Wts 10/11/2027 涨幅较大,苏轩堂、Akanda Corp.、Painreform Ltd.较为活跃,换手率分别为16.98%、16.89%、10.73%,振幅较大的相关个股有Redhill Biopharma Ltd、Durect Corporation、Painreform Ltd.,振幅分别为17.23%、17.11%、17.09%。Supernus Pharmaceuticals, Inc.公司简介:Supernus Pharmaceuticals Inc 是一家专业制药公司,致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080522390296823fba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080522390296823fba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SUPN"],"gpt_icon":0},{"id":"2456262475","title":"Supernus Pharmaceuticals Inc 预计每股收益39美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2456262475","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456262475?lang=zh_cn&edition=full","pubTime":"2024-08-03 07:24","pubTimestamp":1722641051,"startTime":"0","endTime":"0","summary":" * Supernus Pharmaceuticals Inc 预计将在 8 月 6 日公布截至 0001 年 1 月 1 日的季度收入报告。* LSEG 分析师对 Supernus Pharmaceuticals Inc 的平均预期为每股收益 39 美分。* 华尔街对 Supernus Pharmaceuticals Inc 的 12 个月目标价中位数为 40.50 美元,高于其最新收盘价 28.78 美元。8月2日 - 上一季度业绩。除非另有说明,所有数字均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Supernus Pharmaceuticals Inc 预计每股收益39美分 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SUPN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.supernus.com","stockEarnings":[{"period":"1week","weight":-0.0205},{"period":"1month","weight":-0.0191},{"period":"3month","weight":0.1135},{"period":"6month","weight":0.3103},{"period":"1year","weight":0.2384},{"period":"ytd","weight":0.2243}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Supernus Pharmaceuticals, Inc.于2005年3月30日在美国特拉华州注册成立,并于2005年12月22日开始运营。该公司是一家专业制药公司,专注于开发和商业化产品,为治疗中枢神经系统疾病,包括神经和精神治疗紊乱。公司有两个专利产品和几个专有候选产品的临床开发,可满足癫痫症和注意力缺陷多动障碍的市场需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.06073},{"month":2,"riseRate":0.5,"avgChangeRate":-0.005563},{"month":3,"riseRate":0.5,"avgChangeRate":0.04471},{"month":4,"riseRate":0.666667,"avgChangeRate":0.029799},{"month":5,"riseRate":0.583333,"avgChangeRate":0.055002},{"month":6,"riseRate":0.692308,"avgChangeRate":0.104624},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027741},{"month":8,"riseRate":0.538462,"avgChangeRate":-0.004551},{"month":9,"riseRate":0.307692,"avgChangeRate":-0.02909},{"month":10,"riseRate":0.461538,"avgChangeRate":-0.013491},{"month":11,"riseRate":0.615385,"avgChangeRate":0.006844},{"month":12,"riseRate":0.461538,"avgChangeRate":-0.014909}],"exchange":"NASDAQ","name":"Supernus Pharmaceuticals","nameEN":"Supernus Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Supernus Pharmaceuticals(SUPN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Supernus Pharmaceuticals(SUPN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Supernus Pharmaceuticals,SUPN,Supernus Pharmaceuticals股票,Supernus Pharmaceuticals股票老虎,Supernus Pharmaceuticals股票老虎国际,Supernus Pharmaceuticals行情,Supernus Pharmaceuticals股票行情,Supernus Pharmaceuticals股价,Supernus Pharmaceuticals股市,Supernus Pharmaceuticals股票价格,Supernus Pharmaceuticals股票交易,Supernus Pharmaceuticals股票购买,Supernus Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Supernus Pharmaceuticals(SUPN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Supernus Pharmaceuticals(SUPN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}